Fluorouracil

Manufacturer
Mylan Pharmaceuticals Inc.
Effective date
2021-06-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
11
Source
full-release
Hydrated at
2026-05-31 20:51:18

Label at a glance#

ProductFluorouracil
Active ingredientFLUOROURACIL
Label structure11 sections

Indications and uses

Fluorouracil 5% Topical Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior t...

Dosage and administration

When Fluorouracil 5% Topical Cream is applied to a lesion, a response occurs with the following sequence: erythema, usually followed by vesiculation, desquamation, erosion, and re-epithelialization. Fluorouracil 5% Topical Cream should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil 5% Topical Cream is applied with the fingers, the hands should be washed immediately afterward. A...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Fluorouracil 5% Topical Cream is a topical preparation containing the fluorinated pyrimidine 5-fluorouracil, an antineoplastic antimetabolite.

Fluorouracil 5% Topical Cream contains 5% fluorouracil in a vanishing cream base consisting of methylparaben, polysorbate 60, propylene glycol, propylparaben, purified water, stearyl alcohol, and white petrolatum.

Chemically, fluorouracil is a 5-fluoro-2,4(1H,3H)-pyrimidinedione. It is a white to practically white crystalline powder which is sparingly soluble in water and slightly soluble in alcohol. One gram of fluorouracil is soluble in 100 mL of propylene glycol. The molecular weight of 5-fluorouracil is 130.08 and the structural formula is:

Fluorouracil Structural Formula
Fluorouracil Structural Formula

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

There is evidence that the metabolism of fluorouracil in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid. In this manner, fluorouracil interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency which provokes unbalanced growth and death of the cell. The effects of DNA and RNA deprivation are most marked on those cells which grow more rapidly and take up fluorouracil at a more rapid rate. The catabolic metabolism of fluorouracil results in degradation products (e.g., CO2, urea, α-fluoro-β-alanine) which are inactive.

Systemic absorption studies of topically applied fluorouracil have been performed on patients with actinic keratoses using tracer amounts of 14C-labeled fluorouracil added to a 5% preparation. All patients had been receiving nonlabeled fluorouracil until the peak of the inflammatory reaction occurred (2 to 3 weeks), ensuring that the time of maximum absorption was used for measurement. One gram of labeled preparation was applied to the entire face and neck and left in place for 12 hours. Urine samples were collected. At the end of 3 days, the total recovery ranged between 0.48% and 0.94% with an average of 0.76%, indicating that approximately 5.98% of the topical dose was absorbed systemically. If applied twice daily, this would indicate systemic absorption of topical fluorouracil to be in the range of 5 to 6 mg per daily dose of 100 mg. In an additional study, negligible amounts of labeled material were found in plasma, urine, and expired CO2 after 3 days of treatment with topically applied 14C-labeled fluorouracil.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Fluorouracil 5% Topical Cream is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established.

The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil 5% Topical Cream is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Fluorouracil 5% Topical Cream may cause fetal harm when administered to a pregnant woman.

There are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. One birth defect (cleft lip and palate) has been reported in the newborn of a patient using Fluorouracil 5% Topical Cream as recommended. One birth defect (ventricular septal defect) and cases of miscarriage have been reported when Fluorouracil 5% Topical Cream was applied to mucous membrane areas. Multiple birth defects have been reported in a fetus of a patient treated with intravenous fluorouracil.

Animal reproduction studies have not been conducted with Fluorouracil 5% Topical Cream. Fluorouracil administered parenterally has been shown to be teratogenic in mice, rats, and hamsters when given at doses equivalent to the usual human intravenous dose; however, the amount of fluorouracil absorbed systemically after topical administration to actinic keratoses is minimal (see CLINICAL PHARMACOLOGY). Fluorouracil exhibited maximum teratogenicity when given to mice as single intraperitoneal injections of 10 to 40 mg/kg on Day 10 or 12 of gestation. Similarly, intraperitoneal doses of 12 to 37 mg/kg given to rats between Days 9 and 12 of gestation and intramuscular doses of 3 to 9 mg/kg given to hamsters between Days 8 and 11 of gestation were teratogenic and/or embryotoxic (i.e., resulted in increased resorptions or embryolethality). In monkeys, divided doses of 40 mg/kg given between Days 20 and 24 of gestation were not teratogenic. Doses higher than 40 mg/kg resulted in abortion.

Fluorouracil 5% Topical Cream should not be used in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. A large percentage of fluorouracil is catabolized by the DPD enzyme. DPD enzyme deficiency can result in shunting of fluorouracil to the anabolic pathway, leading to cytotoxic activity and potential toxicities.

Fluorouracil 5% Topical Cream is contraindicated in women who are or may become pregnant during therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus.

Fluorouracil 5% Topical Cream is also contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration. Additionally, cases of miscarriage and a birth defect (ventricular septal defect) have been reported when Fluorouracil 5% Topical Cream was applied to mucous membrane areas during pregnancy.

Occlusion of the skin with resultant hydration has been shown to increase percutaneous penetration of several topical preparations. If any occlusive dressing is used in treatment of basal cell carcinoma, there may be an increase in the severity of inflammatory reactions in the adjacent normal skin. A porous gauze dressing may be applied for cosmetic reasons without increase in reaction.

Exposure to ultraviolet rays should be minimized during and immediately following treatment with Fluorouracil 5% Topical Cream because the intensity of the reaction may be increased.

Patients should discontinue therapy with Fluorouracil 5% Topical Cream if symptoms of DPD enzyme deficiency develop (see CONTRAINDICATIONS).

Rarely, life-threatening toxicities such as stomatitis, diarrhea, neutropenia, and neurotoxicity have been reported with intravenous administration of fluorouracil in patients with DPD enzyme deficiency. One case of life-threatening systemic toxicity has been reported with the topical use of Fluorouracil 5% Topical Cream in a patient with DPD enzyme deficiency. Symptoms included severe abdominal pain, bloody diarrhea, vomiting, fever, and chills. Physical examination revealed stomatitis, erythematous skin rash, neutropenia, thrombocytopenia, inflammation of the esophagus, stomach, and small bowel. Although this case was observed with 5% fluorouracil cream, it is unknown whether patients with profound DPD enzyme deficiency would develop systemic toxicity with lower concentrations of topically applied fluorouracil.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

There is a possibility of increased absorption through ulcerated or inflamed skin.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients should be forewarned that the reaction in the treated areas may be unsightly during therapy and, usually, for several weeks following cessation of therapy. Patients should be instructed to avoid exposure to ultraviolet rays during and immediately following treatment with Fluorouracil 5% Topical Cream because the intensity of the reaction may be increased. If Fluorouracil 5% Topical Cream is applied with the fingers, the hands should be washed immediately afterward. Fluorouracil 5% Topical Cream should not be applied on the eyelids or directly into the eyes, nose, or mouth because irritation may occur.

Fluorouracil, including Fluorouracil 5% Topical Cream may be fatal if ingested by pets. Avoid allowing pets to contact the Fluorouracil 5% Topical Cream container or the skin where Fluorouracil 5% Topical Cream has been applied. Store Fluorouracil 5% Topical Cream out of reach of pets. Safely discard or clean any cloth or applicator that may retain Fluorouracil 5% Topical Cream and avoid leaving any residues of Fluorouracil 5% Topical Cream on your hands, clothing, carpeting or furniture.

Laboratory Tests

LABORATORY TESTS SECTION

Solar keratoses which do not respond should be biopsied to confirm the diagnosis. Follow-up biopsies should be performed as indicated in the management of superficial basal cell carcinoma.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Adequate long-term studies in animals to evaluate carcinogenic potential have not been conducted with fluorouracil. Studies with the active ingredient of Fluorouracil 5% Topical Cream, 5-fluorouracil, have shown positive effects in in vitro tests for mutagenicity and on impairment of fertility.

5-Fluorouracil was positive in three in vitro cell neoplastic transformation assays. In the C3H/10T½ clone 8 mouse embryo cell system, the resulting morphologically transformed cells formed tumors when inoculated into immunosuppressed syngeneic mice.

While no evidence for mutagenic activity was observed in the Ames test (three studies), fluorouracil has been shown to be mutagenic in the survival count rec-assay with Bacillus subtilis and in the Drosophila wing-hair spot test. Fluorouracil produced petite mutations in Saccharomyces cerevisiae and was positive in the micronucleus test (bone marrow cells of male mice).

Fluorouracil was clastogenic in vitro (i.e., chromatid gaps, breaks, and exchanges) in Chinese hamster fibroblasts at concentrations of 1.0 and 2.0 mcg/mL and has been shown to increase sister chromatid exchange in vitro in human lymphocytes. In addition, 5-fluorouracil has been reported to produce an increase in numerical and structural chromosome aberrations in peripheral lymphocytes of patients treated with this product.

Doses of 125 to 250 mg/kg, administered intraperitoneally, have been shown to induce chromosomal aberrations and changes in chromosome organization of spermatogonia in rats. Spermatogonial differentiation was also inhibited by fluorouracil, resulting in transient infertility. However, in studies with a strain of mouse which is sensitive to the induction of sperm head abnormalities after exposure to a range of chemical mutagens and carcinogens, fluorouracil was inactive at oral doses of 5 to 80 mg/kg/day. In female rats, fluorouracil administered intraperitoneally at doses of 25 and 50 mg/kg during the preovulatory phase of oogenesis significantly reduced the incidence of fertile matings, delayed the development of preimplantation and postimplantation embryos, increased the incidence of preimplantation lethality and induced chromosomal anomalies in these embryos. Single-dose intravenous and intraperitoneal injections of 5-fluorouracil have been reported to kill differentiated spermatogonia and spermatocytes (at 500 mg/kg) and to produce abnormalities in spermatids (at 50 mg/kg) in mice.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether Fluorouracil 5% Topical Cream is excreted in human milk. Because there is some systemic absorption of fluorouracil after topical administration (see CLINICAL PHARMACOLOGY), because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue use of the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to Fluorouracil 5% Topical Cream occur locally and are often related to an extension of the pharmacological activity of the drug. These include burning, crusting, allergic contact dermatitis, pruritus, scarring, rash, soreness, and ulceration. Ulcerations, other local reactions, cases of miscarriage, and a birth defect (ventricular septal defect) have been reported when Fluorouracil 5% Topical Cream was applied to mucous membrane areas. Leukocytosis is the most frequent hematological side effect.

Although a causal relationship is remote, other adverse reactions which have been reported infrequently are:

Central Nervous System: Emotional upset, insomnia, irritability.

Gastrointestinal: Medicinal taste, stomatitis.

Hematological: Eosinophilia, thrombocytopenia, toxic granulation.

Integumentary: Alopecia, blistering, bullous pemphigoid, discomfort, ichthyosis, scaling, suppuration, swelling, telangiectasia, tenderness, urticaria, skin rash.

Special Senses: Conjunctival reaction, corneal reaction, lacrimation, nasal irritation.

Miscellaneous: Herpes simplex.

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

There have been no reports of overdosage with Fluorouracil 5% Topical Cream.

The oral LD50 for the 5% topical cream was 234 mg/kg in rats and 39 mg/kg in dogs. These doses represented 11.7 and 1.95 mg/kg of fluorouracil, respectively. Studies with a 5% topical solution yielded an oral LD50 of 214 mg/kg in rats and 28.5 mg/kg in dogs, corresponding to 10.7 and 1.43 mg/kg of fluorouracil, respectively. The topical application of the 5% cream to rats yielded an LD50 of greater than 500 mg/kg.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

When Fluorouracil 5% Topical Cream is applied to a lesion, a response occurs with the following sequence: erythema, usually followed by vesiculation, desquamation, erosion, and re-epithelialization.

Fluorouracil 5% Topical Cream should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil 5% Topical Cream is applied with the fingers, the hands should be washed immediately afterward.

Actinic or Solar Keratosis

SPL UNCLASSIFIED SECTION

Apply cream or solution twice daily in an amount sufficient to cover the lesions. Medication should be continued until the inflammatory response reaches the erosion stage, at which time use of the drug should be terminated. The usual duration of therapy is from 2 to 4 weeks. Complete healing of the lesions may not be evident for 1 to 2 months following cessation of Fluorouracil 5% Topical Cream therapy.

Superficial Basal Cell Carcinomas

SPL UNCLASSIFIED SECTION

Only the 5% strength is recommended. Apply cream or solution twice daily in an amount sufficient to cover the lesions. Treatment should be continued for at least 3 to 6 weeks. Therapy may be required for as long as 10 to 12 weeks before the lesions are obliterated. As in any neoplastic condition, the patient should be followed for a reasonable period of time to determine if a cure has been obtained.

HOW SUPPLIED

HOW SUPPLIED SECTION

Fluorouracil 5% Topical Cream is available in 40 g tubes containing 5% fluorouracil (NDC 0378-4791-06) in a vanishing cream base consisting of methylparaben, polysorbate 60, propylene glycol, propylparaben, purified water, stearyl alcohol, and white petrolatum.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

1337.3

Revised: 6/2021
FLUOR:R3

PRINCIPAL DISPLAY PANEL – 5%

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0378-4791-06    Rx only

Fluorouracil
Topical Cream   5%

FOR TOPICAL USE ONLY - NOT FOR
OPHTHALMIC, ORAL, OR INTRAVAGINAL USE

40 g

Each gram contains: 5% fluorouracil in a vanishing cream base consisting of methylparaben, polysorbate 60, propylene glycol, propylparaben, purified water, stearyl alcohol, and white petrolatum.

Apply preferably with a nonmetal applicator or suitable glove.

Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Product of Mexico

Usual Dosage: For dosage recommendations and other important prescribing information, see accompanying insert.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

FOR TOPICAL USE ONLY

Keep out of reach of children.
May be fatal if your pet licks or ingests.
Avoid allowing pets to contact this tube or your skin where Fluorouracil 5%
Topical Cream has been applied. Store and dispose out of the reach of pets.

M:4791:06:1C:R6
1231.6

Fluorouracil Topical Cream 5% Carton Label
Fluorouracil Topical Cream 5% Carton Label

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
FLUOROURACIL Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
7dc9482d-9b87-4471-9708-4f1b4585846bProduct name220250723
a2ca0bf8-8306-49cc-93a3-3e6e4137c7cbProduct name520250630
dc0d2364-4811-4665-a3ee-7ed8c7301465Product name220171219
62fb8671-1693-49d8-8aab-0c1bfdd6794eProduct name120151005
878ca466-81fd-9d24-1349-31baf36065c6Product name220150506
630d1bc2-ae6b-fd31-1264-c4733e788193Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0378-4791-06Fluorouracil1 in 1 CARTONCREAM111
0378-4791-06Fluorouracil40 g in 1 TUBECREAM4011

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0378-4791FLUOROURACIL CREAM [MYLAN PHARMACEUTICALS INC.]11Current NDC, Legacy NDC, 2 package rows20230708_744737c5-0d96-4214-82ab-6cff016b1ea0.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0378-4791-06GM - Gram0378-4791d4020f81-d7e1-4a5e-ada1-863ebd27a85812013-10-17

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
FluorouracilACTIVE INGREDIENTU3P01618RT2
FluorouracilACTIVE MOIETYU3P01618RT2
methylparabenINACTIVE INGREDIENTA2I8C7HI9T2
petrolatumINACTIVE INGREDIENT4T6H12BN9U2
polysorbate 60INACTIVE INGREDIENTCAL22UVI4M2
propylene glycolINACTIVE INGREDIENT6DC9Q167V32
propylparabenINACTIVE INGREDIENTZ8IX2SC1OH2
stearyl alcoholINACTIVE INGREDIENT2KR89I4H1Y2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0378-47910378-4791-06

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 12 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
methylparabenMETHYLPARABENA2I8C7HI9TCREAM / TOPICAL3000 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
polysorbate 60POLYSORBATE 60CAL22UVI4MCREAM / TOPICAL428 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
petrolatumPETROLATUM4T6H12BN9UCREAM / TOPICAL4213 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TCREAM / TOPICAL3000 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHCREAM / TOPICAL120 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
stearyl alcoholSTEARYL ALCOHOL2KR89I4H1YCREAM / TOPICAL162000 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
stearyl alcoholSTEARYL ALCOHOL2KR89I4H1YCREAM / TOPICAL162000 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
petrolatumPETROLATUM4T6H12BN9UCREAM / TOPICAL4213 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CREAM / TOPICAL76000 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CREAM / TOPICAL76000 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
polysorbate 60POLYSORBATE 60CAL22UVI4MCREAM / TOPICAL428 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHCREAM / TOPICAL120 mgExact identifier — unii+route+dosage form
2 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N016831-001EFUDEXFLUOROURACIL2%SOLUTION / TOPICALATRLD, RS, Approved before 1982
N016831-002EFUDEXFLUOROURACIL5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982
N016831-003EFUDEXFLUOROURACIL5%CREAM / TOPICALABRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
N016831-001AT
N016831-003AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 135 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982d4dbc9d85df4…
2026-11-14 07:37:172026-10N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982d4dbc9d85df4…
2026-11-14 07:37:172026-10N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N016831-002EFUDEX5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**SOLUTION / TOPICALRLD, Approved before 1982d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N016831-003EFUDEX5%CREAM / TOPICALABRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N016831-001EFUDEX2%SOLUTION / TOPICALATRLD, RS, Approved before 1982d06236e962d9…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 94 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N016831-001AT1d4dbc9d85df4…
2026-11-14 07:37:172026-10N016831-003AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09N016831-001AT1c2088c7a36db…
2026-10-15 13:18:302026-09N016831-003AB1c2088c7a36db…
2026-09-14 22:38:342026-08N016831-001AT184e616aacf4f…
2026-09-14 22:38:342026-08N016831-003AB184e616aacf4f…
2026-08-18 06:07:402026-07N016831-001AT1caaa826d4ba7…
2026-08-18 06:07:402026-07N016831-003AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N016831-001AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N016831-003AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016831-001AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N016831-003AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N016831-001AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N016831-003AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016831-001AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N016831-003AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016831-001AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N016831-003AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016831-001AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N016831-003AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N016831-001AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N016831-003AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N016831-001AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N016831-003AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N016831-001AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N016831-003AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N016831-001AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10N016831-003AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N016831-001AT179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N016831-003AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N016831-001AT1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N016831-003AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N016831-001AT11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N016831-003AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N016831-001AT18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N016831-003AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N016831-001AT15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N016831-003AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N016831-001AT15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N016831-003AB15d02ea3f76ae…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FluorouracilFLUOROURACILMylan Pharmaceuticals Inc.744737c5-0d96-4214-82ab-6cff016b1ea02021-06-30Warnings, Adverse reactionsExact identifier
ndc (package): 0378-4791-06
ndc (product): 0378-4791
ndc11 (package): 00378479106
spl id: 1ff72539-1af5-41bf-8720-1ba12df35abc
spl set id: 744737c5-0d96-4214-82ab-6cff016b1ea0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.